Lamotrigine for the treatment of bipolar disorder: A clinical case series

Trisha Suppes, E. Sherwood Brown, Susan L. McElroy, Paul E. Keck, Willem Nolen, Ralph Kupka, Mark A Frye, Kirk D. Denicoff, Lori Altshuler, Gabrielle S. Leverich, Robert M. Post

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Background: Recently, a number of new agents have become available to treat bipolar disorder, however many patients may not respond fully even when used in combination. Early reports in epilepsy studies suggested mood- related effects of lamotrigine treatment, as have preliminary reports in bipolar patients. Methods: Seventeen patients meeting DSM-IV criteria for bipolar I (n = 9) or bipolar II (n = 8) disorder displaying affective symptoms and a past history of inadequate response or tolerability to at least two standard mood stabilizing agents were recruited through the Stanley Foundation Bipolar Network and treated with the new anticonvulsant lamotrigine in an add-on, open-label study. Response to therapy was assessed using the Clinical Global Impression Scale modified for bipolar disorder. Results: The mean dose of lamotrigine was 187±157 mg/day (range 50-600 mg/day) for a mean duration of 159±109 days (range 14-455 days). Eleven (65%) patients were rated as very much or much improved. Lamotrigine was well tolerated, and may have mood stabilizing and antidepressant properties in some patients with bipolar disorder. Limitations: The study is hypothesis generating because it was uncontrolled and open. Controlled studies are warranted. Conclusions: This preliminary report supports clinical improvement for both mood cycling and depression in patients with bipolar disorder treated with lamotrigine.

Original languageEnglish (US)
Pages (from-to)95-98
Number of pages4
JournalJournal of Affective Disorders
Volume53
Issue number1
DOIs
StatePublished - Apr 1 1999
Externally publishedYes

Fingerprint

Bipolar Disorder
Therapeutics
Affective Symptoms
Excipients
Diagnostic and Statistical Manual of Mental Disorders
Anticonvulsants
Antidepressive Agents
lamotrigine
Epilepsy
Depression

Keywords

  • Bipolar depression
  • Bipolar disorder
  • Lamotrigine
  • Mood lability
  • Treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

Suppes, T., Brown, E. S., McElroy, S. L., Keck, P. E., Nolen, W., Kupka, R., ... Post, R. M. (1999). Lamotrigine for the treatment of bipolar disorder: A clinical case series. Journal of Affective Disorders, 53(1), 95-98. https://doi.org/10.1016/S0165-0327(98)00077-9

Lamotrigine for the treatment of bipolar disorder : A clinical case series. / Suppes, Trisha; Brown, E. Sherwood; McElroy, Susan L.; Keck, Paul E.; Nolen, Willem; Kupka, Ralph; Frye, Mark A; Denicoff, Kirk D.; Altshuler, Lori; Leverich, Gabrielle S.; Post, Robert M.

In: Journal of Affective Disorders, Vol. 53, No. 1, 01.04.1999, p. 95-98.

Research output: Contribution to journalArticle

Suppes, T, Brown, ES, McElroy, SL, Keck, PE, Nolen, W, Kupka, R, Frye, MA, Denicoff, KD, Altshuler, L, Leverich, GS & Post, RM 1999, 'Lamotrigine for the treatment of bipolar disorder: A clinical case series', Journal of Affective Disorders, vol. 53, no. 1, pp. 95-98. https://doi.org/10.1016/S0165-0327(98)00077-9
Suppes, Trisha ; Brown, E. Sherwood ; McElroy, Susan L. ; Keck, Paul E. ; Nolen, Willem ; Kupka, Ralph ; Frye, Mark A ; Denicoff, Kirk D. ; Altshuler, Lori ; Leverich, Gabrielle S. ; Post, Robert M. / Lamotrigine for the treatment of bipolar disorder : A clinical case series. In: Journal of Affective Disorders. 1999 ; Vol. 53, No. 1. pp. 95-98.
@article{04f6c12fab2d406799c10d230e4d855d,
title = "Lamotrigine for the treatment of bipolar disorder: A clinical case series",
abstract = "Background: Recently, a number of new agents have become available to treat bipolar disorder, however many patients may not respond fully even when used in combination. Early reports in epilepsy studies suggested mood- related effects of lamotrigine treatment, as have preliminary reports in bipolar patients. Methods: Seventeen patients meeting DSM-IV criteria for bipolar I (n = 9) or bipolar II (n = 8) disorder displaying affective symptoms and a past history of inadequate response or tolerability to at least two standard mood stabilizing agents were recruited through the Stanley Foundation Bipolar Network and treated with the new anticonvulsant lamotrigine in an add-on, open-label study. Response to therapy was assessed using the Clinical Global Impression Scale modified for bipolar disorder. Results: The mean dose of lamotrigine was 187±157 mg/day (range 50-600 mg/day) for a mean duration of 159±109 days (range 14-455 days). Eleven (65{\%}) patients were rated as very much or much improved. Lamotrigine was well tolerated, and may have mood stabilizing and antidepressant properties in some patients with bipolar disorder. Limitations: The study is hypothesis generating because it was uncontrolled and open. Controlled studies are warranted. Conclusions: This preliminary report supports clinical improvement for both mood cycling and depression in patients with bipolar disorder treated with lamotrigine.",
keywords = "Bipolar depression, Bipolar disorder, Lamotrigine, Mood lability, Treatment",
author = "Trisha Suppes and Brown, {E. Sherwood} and McElroy, {Susan L.} and Keck, {Paul E.} and Willem Nolen and Ralph Kupka and Frye, {Mark A} and Denicoff, {Kirk D.} and Lori Altshuler and Leverich, {Gabrielle S.} and Post, {Robert M.}",
year = "1999",
month = "4",
day = "1",
doi = "10.1016/S0165-0327(98)00077-9",
language = "English (US)",
volume = "53",
pages = "95--98",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Lamotrigine for the treatment of bipolar disorder

T2 - A clinical case series

AU - Suppes, Trisha

AU - Brown, E. Sherwood

AU - McElroy, Susan L.

AU - Keck, Paul E.

AU - Nolen, Willem

AU - Kupka, Ralph

AU - Frye, Mark A

AU - Denicoff, Kirk D.

AU - Altshuler, Lori

AU - Leverich, Gabrielle S.

AU - Post, Robert M.

PY - 1999/4/1

Y1 - 1999/4/1

N2 - Background: Recently, a number of new agents have become available to treat bipolar disorder, however many patients may not respond fully even when used in combination. Early reports in epilepsy studies suggested mood- related effects of lamotrigine treatment, as have preliminary reports in bipolar patients. Methods: Seventeen patients meeting DSM-IV criteria for bipolar I (n = 9) or bipolar II (n = 8) disorder displaying affective symptoms and a past history of inadequate response or tolerability to at least two standard mood stabilizing agents were recruited through the Stanley Foundation Bipolar Network and treated with the new anticonvulsant lamotrigine in an add-on, open-label study. Response to therapy was assessed using the Clinical Global Impression Scale modified for bipolar disorder. Results: The mean dose of lamotrigine was 187±157 mg/day (range 50-600 mg/day) for a mean duration of 159±109 days (range 14-455 days). Eleven (65%) patients were rated as very much or much improved. Lamotrigine was well tolerated, and may have mood stabilizing and antidepressant properties in some patients with bipolar disorder. Limitations: The study is hypothesis generating because it was uncontrolled and open. Controlled studies are warranted. Conclusions: This preliminary report supports clinical improvement for both mood cycling and depression in patients with bipolar disorder treated with lamotrigine.

AB - Background: Recently, a number of new agents have become available to treat bipolar disorder, however many patients may not respond fully even when used in combination. Early reports in epilepsy studies suggested mood- related effects of lamotrigine treatment, as have preliminary reports in bipolar patients. Methods: Seventeen patients meeting DSM-IV criteria for bipolar I (n = 9) or bipolar II (n = 8) disorder displaying affective symptoms and a past history of inadequate response or tolerability to at least two standard mood stabilizing agents were recruited through the Stanley Foundation Bipolar Network and treated with the new anticonvulsant lamotrigine in an add-on, open-label study. Response to therapy was assessed using the Clinical Global Impression Scale modified for bipolar disorder. Results: The mean dose of lamotrigine was 187±157 mg/day (range 50-600 mg/day) for a mean duration of 159±109 days (range 14-455 days). Eleven (65%) patients were rated as very much or much improved. Lamotrigine was well tolerated, and may have mood stabilizing and antidepressant properties in some patients with bipolar disorder. Limitations: The study is hypothesis generating because it was uncontrolled and open. Controlled studies are warranted. Conclusions: This preliminary report supports clinical improvement for both mood cycling and depression in patients with bipolar disorder treated with lamotrigine.

KW - Bipolar depression

KW - Bipolar disorder

KW - Lamotrigine

KW - Mood lability

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0032913616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032913616&partnerID=8YFLogxK

U2 - 10.1016/S0165-0327(98)00077-9

DO - 10.1016/S0165-0327(98)00077-9

M3 - Article

C2 - 10363672

AN - SCOPUS:0032913616

VL - 53

SP - 95

EP - 98

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 1

ER -